Aetna announced plans on Thursday, September 27, to sell its Medicare prescription-drug business to WellCare Health Plans, a key step towards gaining regulator approval for its US$67.5 billion merger with CVS.
Although financial terms of the deal weren’t disclosed, in a securities filing, Aetna stated that the “purchase price is not material” to the company. The divestiture of the Medicare Part D to WellCare may help resolve objections to the CVS-Aetna deal from US antitrust regulators.
The company stated in the filing that, “Aetna believes the divestiture is a significant step toward completing the DOJ’s (Department of Justice) review.”
WellCare, a smaller health insurer that’s based in Tampa, Florida, has been using deals to fuel its expansion. The company completed a US$2.5 billion deal for the health insurer Meridian in early September, adding about 1.1 million insurance customers to its base of 4.4 million members.
Full Content: Reuters
Featured News
House Committee Subpoenas Vanguard and Arjuna Capital in Antitrust Probe
Dec 11, 2023 by
CPI
IAG Seeks EU Antitrust Approval for Air Europa Buyout, Pledges Remedies
Dec 11, 2023 by
CPI
Google Antitrust Trial Shifts to Jury for Decision
Dec 11, 2023 by
CPI
Cigna Ends Acquisition Talks with Humana Amid Price Disagreement
Dec 11, 2023 by
CPI
Sen. Warren Accuses Apple of Profit-Driven Blocking Amid iMessage Access Controversy
Dec 11, 2023 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Right to Repair
Dec 11, 2023 by
CPI
States Do-it-Themselves: Amid Spotty Federal Enforcement, State Legislatures are Revamping Right-to-Repair Laws at an Unprecedented Pace
Dec 11, 2023 by
CPI
All Tied Up? The Evolving Consumer Protection Focus on Repair Restrictions
Dec 11, 2023 by
CPI
Right to Repair is Rooted in Antitrust Law
Dec 11, 2023 by
CPI
Right to Repair: A Case Study for the Maturation of a Regulatory Issue
Dec 11, 2023 by
CPI